PALI vs. ORGS, SLGL, ABVC, TXMD, MRKR, IBIO, IXHL, MBRX, BGXX, and RLYB
Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Orgenesis (ORGS), Sol-Gel Technologies (SLGL), ABVC BioPharma (ABVC), TherapeuticsMD (TXMD), Marker Therapeutics (MRKR), iBio (IBIO), Incannex Healthcare (IXHL), Moleculin Biotech (MBRX), Bright Green (BGXX), and Rallybio (RLYB). These companies are all part of the "pharmaceutical products" industry.
Palisade Bio vs.
Palisade Bio (NASDAQ:PALI) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, community ranking, profitability, media sentiment, earnings, risk and valuation.
Palisade Bio received 9 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote.
Palisade Bio has higher earnings, but lower revenue than Orgenesis.
Palisade Bio has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Palisade Bio presently has a consensus price target of $23.00, suggesting a potential upside of 3,027.12%. Given Palisade Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Palisade Bio is more favorable than Orgenesis.
Palisade Bio has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Palisade Bio's return on equity.
In the previous week, Palisade Bio had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Palisade Bio and 0 mentions for Orgenesis. Palisade Bio's average media sentiment score of 0.80 beat Orgenesis' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.
11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 3.3% of Palisade Bio shares are held by company insiders. Comparatively, 5.7% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Palisade Bio beats Orgenesis on 10 of the 16 factors compared between the two stocks.
Get Palisade Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Palisade Bio Competitors List
Related Companies and Tools
This page (NASDAQ:PALI) was last updated on 4/25/2025 by MarketBeat.com Staff
